CD4 and neoplasm: Upon recognition of tumour‐associated antigens presented via MHC‐II, CD4+ T cells can differentiate into distinct effector subsets, including Th1 cells that promote cytotoxic activity through IFN‐γ and TNF‐α production, and Tfh cells that support B cell–mediated humoral immunity.102, 103